硕世生物 (688399)
Jiangsu Bioperfectus Technologies Co., Ltd.
K-Line Chart
No K-line data available
Company NameJiangsu Shuoshi Biotechnology Co., Ltd.
Listing Date2019-12-05
Issue Price46.78RMB
Registered Capital5667.008210k RMB
Legal RepresentativeWang Guoqiang
Registered AddressNo. 837 Yaocheng Avenue, Taizhou City, Jiangsu Province
IndustryMedical Devices
Main BusinessThe company focuses on the research and development, production, and sales of in vitro diagnostic products such as diagnostic reagents and supporting testing instruments, and has expanded into the field of in vitro testing services, achieving an integrated business model of "Instrument + Reagent + Service." The company possesses modern biological technology platforms including nucleic acid molecular detection reagents, multiplex fluorescent quantitative PCR, and dry chemistry. Currently, it has over 500 products widely used in areas such as infectious disease prevention and control, clinical testing, large-scale population screening, and eugenics and fertility management.
Company ProfileJiangsu Shuoshi Biotechnology Co., Ltd. was founded in 2010 and is located in the China Medical City, a national-level pharmaceutical high-tech park in Taizhou, Jiangsu. The company has built two clean production workshops for nucleic acids and proteins that comply with national medical device production quality management standards. It has passed ISO13485 quality system certification and is a high-tech biotechnology enterprise integrating R&D, production, and sales. The company was consecutively certified as a National High-Tech Enterprise in 2013 and 2016.
The company possesses modern biological technology platforms such as multiplex fluorescent quantitative PCR and enzyme chemistry, and is engaged in product R&D, production, and sales in fields including disease prevention and control, female reproductive tract microecological testing, and tumor screening. It has successfully developed nearly 500 products for infectious pathogen detection, female reproductive tract microecological testing, tumor screening, etc., with many products having obtained Class III or Class II product registration certificates issued by the Medical Products Administration. The company is a major supplier of nucleic acid-based detection products in the field of disease prevention and control and a key supplier of female lower reproductive tract microecological testing products in the clinical gynecological testing field.
Stock Details
1. Key Indicators
- Total Shares(W): 8387.17
- Circulating A-Shares(W): 8387.17
- Earnings Per Share(RMB): 0.0400
- Net Assets Per Share(RMB): 35.3825
- Operating Revenue(W RMB): 25750.78
- Total Profit(W RMB): 712.55
- **Net Profit Attributable to Parent(W RMB) **: 315.17
- Net Profit Growth Rate(%): -88.38
- Weighted Return on Equity(%): 0.1000
- Operating Cash Flow Per Share(RMB): 0.2320
- Undistributed Profit Per Share(RMB): 26.5472
- Capital Reserve Per Share(RMB): 7.5578
2. Main Business
The main business covers:
- Research, development, production and sales of in vitro diagnostic reagents
- Research, development, production and sales of supporting testing instruments
- Research, development, production and sales of other in vitro diagnostic products
3. Company Basic Information
- Company Name: Jiangsu Shuoshi Biotechnology Co., Ltd.
- Listing Date: 2019-12-05
- Industry: Pharmaceutical Manufacturing
- Address: No. 837 Yaocheng Avenue, Taizhou City, Jiangsu Province
- Website: http://www.s-sbio.com/
- Company Profile: The company's predecessor Shuoshi Limited was established in April 2010 with a registered capital of RMB 30 million. On April 12, 2010, Shuoshi Limited completed its establishment registration and obtained the Business License. The company was transformed into a joint stock company based on the audited net assets as of October 31, 2016, with a total share capital of 43.96 million shares. On April 10, 2017, Shuoshi Biotechnology completed the establishment registration of the joint stock company at the Taizhou Administration for Industry and Commerce and obtained the Business License.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shaoxing Runkan Biomedical Equity Investment Partnership (Limited Partnership) | General Legal Person | 2308.80 | 27.53 |
| 2 | Taizhou Shuokang Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 159.84 | 1.91 |
| 3 | Taizhou Shuoyuan Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 159.84 | 1.91 |
| 4 | Shenzhen Qianhai Rongqi Fund Management Co., Ltd. - Rongqi Langyage No. 2 Private Securities Investment Fund | Private Securities Investment Fund | 83.56 | 1.00 |
| 5 | China Galaxy Securities Co., Ltd. | Securities Company | 77.98 | 0.93 |
| 6 | Shenzhen Qianhai Rongqi Fund Management Co., Ltd. - Rongqi Langyage No. 6 Private Securities Investment Fund | Private Securities Investment Fund | 65.65 | 0.78 |
5. Concept Sectors
- Gene Concept
- Vitamin
- Hepatitis Concept
- AI Healthcare
- Margin Trading & Securities Lending
- Heavily Held by Securities Companies
- High Dividend Stocks
- Non-Recurring Loss
- Continuous Loss
- Specialized, Refined, Special and New Enterprises
- New Private Placement
- Sci-Tech Innovation 200
Remarks
- Data update date: 2025-09-30
- Data source: Public market information